A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data on the effectiveness of antipsychotics in the early phase of schizophrenia are limited. The authors examined the risk of rehospitalization and drug discontinuation in a nationwide cohort of 2,588 consecutive patients hospitalized for the first time with a diagnosis of schizophrenia between 2000 and 2007 in Finland. METHOD: The authors linked national databases of hospitalization, mortality, and antipsychotic prescriptions and computed hazard ratios, adjusting for the effects of sociodemographic and clinical variables, the temporal sequence of the antipsychotics used, and the choice of the initial antipsychotic for each patient. RESULTS: Of 2,588 patients, 1,507 (58.2%) collected a prescription for an antipsychotic during the first 30 days after hospital discharge, and 1,182 (45.7%, 95% confidence interval [CI]=43.7-47.6) continued their initial treatment for 30 days or longer. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications (adjusted hazard ratio=0.36, 95% CI=0.17-0.75). Compared with oral risperidone, clozapine (adjusted hazard ratio=0.48, 95% CI=0.31-0.76) and olanzapine (adjusted hazard ratio=0.54, 95% CI=0.40-0.73) were each associated with a significantly lower rehospitalization risk. Use of any antipsychotic compared with no antipsychotic was associated with lower mortality (adjusted hazard ratio=0.45, 95% CI=0.31-0.67). CONCLUSIONS: In Finland, only a minority of patients adhere to their initial antipsychotic during the first 60 days after discharge from their first hospitalization for schizophrenia. Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds. Among oral antipsychotics, clozapine and olanzapine were associated with more favorable outcomes. Use of any antipsychotic was associated with lower mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2×
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Self-citationMedication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Research works printed but not linked: 3
- National Institute for Health and Clinical Excellence (NICE), 2009, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)
- Young JL, 1986, Bull Am Acad Psychiatry Law, 14, 105
- Young JL, 1999, J Am Acad Psychiatry Law, 27, 426
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Self-citationBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationMarder, S. R., & Cannon, T. D. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1808803 · Cited by 529
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 513
The nature of relapse in schizophrenia
Emsley, R., Chiliza, B., Asmal, L., & Harvey, B. H. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-50 · Cited by 478
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395
Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07530 · Cited by 361
Howes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S., & Taylor, D. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 353
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4320 · Cited by 297
Self-citationThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review
Olivares, J. M., Sermon, J., Hemels, M., & Schreiner, A. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-32 · Cited by 270
“56) [136].”
Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.010 · Cited by 262
Self-citationPolypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
Tiihonen, J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1532 · Cited by 253
Self-citationMarcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.9.754 · Cited by 248
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 228
Sabe, M., Pillinger, T., Kaiser, S., Chen, C., Taipale, H., Tanskanen, A., Tiihonen, J., Leucht, S., Correll, C. U., & Solmi, M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104608 · Cited by 213
Self-citationKane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 208
Antipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208
Self-citationTiihonen, J., Mittendorfer-Rutz, E., Torniainen, M., Alexanderson, K., & Tanskanen, A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15050618 · Cited by 203
Self-citationTiihonen, J., Tanskanen, A., & Taipale, H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17091001 · Cited by 196
Self-citationKaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201
Converting oral to long-acting injectable antipsychotics: a guide for the perplexed
Meyer, J. M. (2017) · CNS Spectrums · doi:10.1017/s1092852917000840 · Cited by 196
The Treatment of Hallucinations in Schizophrenia Spectrum Disorders
Sommer, I. E. C., Slotema, C. W., Daskalakis, Z. J., Derks, E. M., Blom, J. D., & van der Gaag, M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs034 · Cited by 194
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186
Kirson, N. Y., Weiden, P. J., Yermakov, S., Huang, W., Samuelson, T., Offord, S. J., Greenberg, P. E., & Wong, B. J. O. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08167 · Cited by 174
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030332 · Cited by 173
Correll, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022) · CNS Drugs · doi:10.1007/s40263-022-00932-2 · Cited by 162
Naber, D., Hansen, K., Forray, C., Baker, R. A., Sapin, C., Beillat, M., Peters-Strickland, T. S., Nylander, A., Hertel, P., Andersen, H. S., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.007 · Cited by 156
Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx176 · Cited by 153
Self-citationFleischhacker, W. W., Sanchez, R., Perry, P. P., Jin, N., Peters-Strickland, T. S., Johnson, B. R., Baker, R. A., Eramo, A., McQuade, R. D., Carson, W. H., et al. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.134213 · Cited by 156
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 182
Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Mortality in schizophrenia: 30-year nationwide follow-up study
Tanskanen, A., Tiihonen, J., & Taipale, H. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12913 · Cited by 134
Self-citationPrediction of disability in schizophrenia: Symptoms, cognition, and self-assessment
Harvey, P. D., Strassnig, M., & Silberstein, J. (2019) · Journal of Experimental Psychopathology · doi:10.1177/2043808719865693 · Cited by 169
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.01.012 · Cited by 131
“[16,17] reported on two large-scale, observational, follow-up studies using a national registry of patients with schizophrenia in Finland.”
BackgroundMeltzer, H. Y., Risinger, R. C., Nasrallah, H. A., Du, Y., Zummo, J., Corey, L., Bose, A., Stankovic, S., Silverman, B. L., & Ehrich, E. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09741 · Cited by 116
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Karson, C. N., Duffy, R. A., Eramo, A., Nylander, A., & Offord, S. J. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s96392 · Cited by 125
Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
Wang, G., Zheng, W., Li, X.-B., Wang, S.-B., Cai, D.-B., Yang, X.-H., Ungvari, G. S., Xiang, Y., & Correll, C. U. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.002 · Cited by 111
Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
Lahti‐Pulkkinen, M., Tiihonen, J., Wildgust, H. J., Beary, M., Hodgson, R. E., Kajantie, E., Osmond, C., Räikkönen, K., & Eriksson, J. G. (2012) · Psychological Medicine · doi:10.1017/s0033291712000396 · Cited by 119
Self-citationZhornitsky, S., & Stip, É. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/407171 · Cited by 111
Japanese Society of Neuropsychopharmacology (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12193 · Cited by 117
Pilon, D., Tandon, N., Lafeuille, M., Kamstra, R. L., Émond, B., Lefèbvre, P., & Joshi, K. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.008 · Cited by 103
Bodén, R., Brandt, L., Kieler, H., Andersen, M. T., & Reutfors, J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.08.024 · Cited by 113
Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J., Brunette, M. F., Estroff, S. E., Mueser, K. T., Penn, D. L., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101355 · Cited by 104
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Parellada, E., & Bioque, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0350-7 · Cited by 93
Schizophrenia: One Name, Many Different Manifestations
Faden, J., & Citrome, L. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.05.005 · Cited by 131
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 98
Schneider‐Thoma, J., Efthimiou, O., Huhn, M., Krause, M., Reichelt, L., Röder, H., Davis, J. M., Salanti, G., & Leucht, S. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30177-9 · Cited by 104
New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
Citrome, L. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811984 · Cited by 85
Beary, M., Hodgson, R., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440512 · Cited by 79
“The use of antipsychotics is an important factor in reducing mortality in schizophrenia (Tiihonen et al., 2006, 2009, 2011), but in contrast a systematic review found some evidence that long-term exposure to antipsychotics increases mortality in schizophrenia (Weinmann et al., 2009).”
BackgroundInfluentialDeterminants of adherence to treatment in first-episode psychosis: a comprehensive review
Leclerc, E., Noto, C., Bressan, R. A., & Brietzke, E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1539 · Cited by 78
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 89
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 85
A safety evaluation of aripiprazole in the treatment of schizophrenia
Preda, A., & Shapiro, B. B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1832990 · Cited by 84
Kiviniemi, M., Suvisaari, J., Koivumaa-Honkanen, H. T., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.043 · Cited by 84
Long-acting injectable antipsychotics: shall the last be first?
Stahl, S. M. (2014) · CNS Spectrums · doi:10.1017/s1092852913001016 · Cited by 75
Tackling nonadherence in psychiatric disorders: current opinion
Farooq, S., & Naeem, F. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s40777 · Cited by 79
Kane, J. M., McEvoy, J. P., Correll, C. U., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 93
Katona, L., Czobor, P., & Bitter, I. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.034 · Cited by 76
Kim, H. O., Seo, G. H., & Lee, B. C. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-019-0254-2 · Cited by 75
Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study
Buckley, P. F., Schooler, N. R., GOFF, D. C., Hsiao, J., Kopelowicz, A. J., Lauriello, J., Manschreck, T. C., Mendelowitz, A. J., Miller, D. D., Severe, J. B., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu067 · Cited by 78
Zhang, H., Mi, W., Li, L., Shi, Y., & Xiao, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s72367 · Cited by 108
Clozapine resistant schizophrenia: Newer avenues of management
Chakrabarti, S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i8.429 · Cited by 82
Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine
Klemettilä, J.-P., Kampman, O., Seppälä, N., Viikki, M., Hämäläinen, M., Moilanen, E., & Leinonen, E. V. J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.04.049 · Cited by 66
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Miyamoto, S., & Fleischhacker, W. W. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0115-z · Cited by 82
Rauch, A.-S., & Fleischhacker, W. W. (2013) · CNS Drugs · doi:10.1007/s40263-013-0083-9 · Cited by 70
Description of long-term polypharmacy among schizophrenia outpatients
Suokas, J. T., Suvisaari, J., Haukka, J. K., Korhonen, P., & Tiihonen, J. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-012-0586-6 · Cited by 65
Self-citationPark, S., Choi, M. Y., Choi, J., Park, E., Tchoe, H. J., Suh, J. K., Kim, Y. H., Won, S. H., Chung, Y., Bae, K., et al. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.4.361 · Cited by 63
Huang, C.-Y., Fang, S., & Shao, Y. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8810 · Cited by 70
Brain, C., Allerby, K., Sameby, B., Quinlan, P. S., Joas, E., Karilampi, U., Lindström, E., Eberhard, J., Burns, T., & Wærn, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.001 · Cited by 70
Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review
Taylor, M., & Ng, K. Y. B. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412470010 · Cited by 63
Self-citationKirschner, M., Theodoridou, A., Fusar‐Poli, P., Kaiser, S., & Jäger, M. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312464106 · Cited by 63
Long‐acting injectable antipsychotics in early psychosis: a literature review
Emsley, R., Chiliza, B., Asmal, L., Mashile, M., & Fusar‐Poli, P. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12027 · Cited by 61
Treatment resistant schizophrenia – review and a call to action
Lally, J., & Gaughran, F. (2018) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2018.47 · Cited by 68
Veronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58
Long-Acting Injectable Antipsychotics in Children and Adolescents
Lytle, S., McVoy, M. K., & Sajatovic, M. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0055 · Cited by 64
Toto, S., Grohmann, R., Bleich, S., Frieling, H., Maier, H. B., Greil, W., Cordes, J., Schmidt-Kraepelin, C., Kasper, S. F., Stübner, S., et al. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz037 · Cited by 64
Beck, K., McCutcheon, R. A., Bloomfield, M., Gaughran, F., Marques, T. R., MacCabe, J. H., Selvaraj, S., Taylor, D. M., & Howes, O. D. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12327 · Cited by 62
Attard, A., Olofinjana, O., Cornelius, V. R., Curtis, V. A., & Taylor, D. M. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12201 · Cited by 58
Tiihonen, J., Tanskanen, A., Hoti, F., Vattulainen, P., Taipale, H., Mehtälä, J., & Lähteenvuo, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30134-7 · Cited by 58
Self-citationHargarter, L., Chérubin, P., Bergmans, P., Keim, S., Rancāns, E., Bez, Y., Parellada, E., Carpiniello, B., Vidailhet, P., & Schreiner, A. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.11.006 · Cited by 57
Bushe, C., Falk, D. M., Anand, E., Casillas, M., Perrin, E., Chhabra-Khanna, R., & Detke, H. C. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0450-9 · Cited by 55
Lipid based intramuscular long-acting injectables: Current state of the art
Wilkinson, J. M., Ajulo, D., Tamburrini, V., Gall, G. L., Kimpe, K., Holm, R., Belton, P., & Qi, S. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106253 · Cited by 59
Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
Manchanda, R., Chue, P. S., MALLA, A. K., Tibbo, P. G., Roy, M., Williams, R. L., Iyer, S. N., Lutgens, D., & Banks, N. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s02 · Cited by 55
Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
Kim, B., Lee, S., Yang, Y. K., Park, J., & Chung, Y. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/560836 · Cited by 57
Biagi, E., Capuzzi, E., Colmegna, F., Mascarini, A., Brambilla, G., Ornaghi, A., Santambrogio, J., & Clerici, M. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0507-x · Cited by 67
Das, A. K., Malik, A., & Haddad, P. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314542098 · Cited by 54
Self-citationHaddad, P., Kishimoto, T., Correll, C., & Kane, J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000160 · Cited by 58
Self-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 63
Self-citationNielsen, J., Jensen, S. O. W., Friis, R. B., Valentin, J. B., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu128 · Cited by 53
Chi, M. H., Hsiao, C. Y., Chen, K. C., Lee, L.-T., Tsai, H. C., Lee, I. H., Chen, P. S., & Yang, Y. K. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.025 · Cited by 58
Kishi, T., Matsunaga, S., & Iwata, N. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw043 · Cited by 60
Metadata
- Authors
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P.
- Affiliations
- NHS Lothian (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2011-06
- Volume
- 168
- Issue
- 6
- Pages
- 603-609
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160096204
- Cited by
- 619
- References
- 28
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 21 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 32 · 2019: 42 · 2018: 51 · 2017: 55 · 2016: 39 · 2015: 52 · 2014: 42 · 2013: 61 · 2012: 44
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, long-acting injectable antipsychotics, oral antipsychotics, hospital readmission, treatment discontinuation, clozapine, olanzapine, risperidone, mortality, medication adherence, first hospitalization
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Drug Implants, Finland, Hospitalization, Humans, Injections, Middle Aged, Patient Readmission, Schizophrenia, Antipsychotic Agents, Cohort Studies, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.